Low-energy femoral shaft fractures associated with alendronate use.
about
Interventions for treating osteonecrosis of the jaw bones associated with bisphosphonatesAtraumatic intracapsular neck of femur fractures after prolonged bisphosphonate treatment: a new atypical variant?Do bisphosphonates cause femoral insufficiency fractures?Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) projectAmerican Society of Biomechanics Journal of Biomechanics Award 2013: cortical bone tissue mechanical quality and biological mechanisms possibly underlying atypical fractures.Osteoprotective Effect of Echinocystic Acid, a Triterpone Component from Eclipta prostrata, in Ovariectomy-Induced Osteoporotic RatsAssociation between alendronate and atypical femur fractures: a meta-analysis.Long-Term Alendronate Use Not without Consequences?Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate.The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronateBisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.Utility of automated data in identifying femoral shaft and subtrochanteric (diaphyseal) fractures.Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy.Amelioration of type I diabetes-induced osteoporosis by parathyroid hormone is associated with improved osteoblast survivalValidation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data.Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails.Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.Bilateral atypical femoral fractures in a patient with multiple myeloma treated with intravenous bisphosphonate therapy.Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment. Frozen bone with remodelling at the crack.Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone ClubAdverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.Predictors of atypical femoral fractures during long term bisphosphonate therapy: a case series & review of literatureFemoral insufficiency fractures associated with prolonged bisphosphonate therapy.Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy?Zoledronic acid infusion for prevention and treatment of osteoporosisZoledronic acid: clinical utility and patient considerations in osteoporosis and low bone massCumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged ratsSubtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group ReportDesign and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosisQuestioning the association between bisphosphonates and atypical femoral fracturesRole of zoledronic acid in the prevention and treatment of osteoporosis.Bisphosphonates and atypical fractures of femur.Nonoperative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures.Sex and gender considerations in male patients with osteoporosisFracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis.A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.Bilateral femoral insufficiency fractures likely related to long-term alendronate therapyFemoral Shaft Cortical Pathology associated with longterm Alendronate Therapy: A New Classification
P2860
Q24236073-CAC71528-7974-4BF7-A01E-EB6A90731C70Q26744060-E6741A21-BAE4-4506-88A4-E24D2DF8A57BQ27021396-5F5F7D85-FE99-48D9-BB33-5C8EE29A8A33Q27026618-D1DFF7FA-9A5B-464D-B238-BA9C1750AE7FQ27027254-FD2AD820-F372-47DB-BF66-58CB49087D14Q28547628-E06B52F0-795A-45A1-A82E-49083C8DC96EQ33596535-BDC20D2F-219A-4606-89B8-64A27A7E2700Q33633821-05F57C86-7468-46BE-9303-78ABE75AA778Q33660030-32C562E8-13B2-4218-A805-E610098854EEQ33700394-062D0B36-7D9D-418A-AC84-B06B75530718Q33715141-01B7C98E-0D68-4B8B-80D4-C3052BEAB795Q33770535-5491A51B-C969-4FC9-8D9B-AA6F21E275B9Q33898842-11821D17-318B-4265-B2B2-ED45AAE256A1Q33910434-3DD585F6-5FD5-40A8-8F80-B0DC7CB54659Q33958113-418C3BA9-69F7-4324-B922-FDCED20A5FD9Q33984172-8221963B-5C9A-42DF-8E9E-B6975AB3AAADQ34018048-C1CB6BD2-FAB4-4A3A-B4DA-F07CF89E0C63Q34032539-7346DAC4-B6AA-4BE6-8E97-81CFF815A537Q34041189-3ECEE0FD-63D9-47CA-908D-90AE79512A1EQ34050326-E49E4708-D42E-4B14-AD00-DC92E494D87FQ34099162-A11B215C-5D0B-463D-883C-C8B593151555Q34189582-B9BB33B6-C807-4EC2-AD7F-2603A924F448Q34272136-91799658-BBFF-4593-B04E-77A671E19828Q34283690-22E290AD-39CE-4D79-9D2A-8FC30DD85DE3Q34283772-8010CDF8-F1E5-491C-9BF0-5934EBF4A721Q34345697-032CB550-35FF-4C25-A8A5-DC656230BB4CQ34389524-734DDD07-BE29-4C5C-A401-0922D25958B6Q34395462-46932CAD-403A-447F-B538-A9C20F3D2B96Q34411999-067EA7BA-FE92-45CB-BB8A-5E93D1053087Q34486831-A04C3A71-9F38-4B86-8E9D-0FAB305B55C9Q34503439-97CCA44C-C518-4A38-9C85-8A4C9D0DDAB6Q34899110-F4AC83A3-A9FE-42EB-85FA-C4B300DE55A7Q34984177-05224798-E5A1-491F-A4FE-04AD5C381AC8Q34986933-B319D43A-8F25-4A28-9B7F-9600A1D91A8BQ35036461-CBA42534-4CFD-4EDF-A494-66DBFC9AF395Q35036493-E4CAC707-5B21-41F0-8E67-B20264A1BD98Q35050241-0F6F89A3-717C-4253-83F0-8EF4368CBD39Q35050731-668345C6-52CD-43E2-8CCB-9278D6CA1FE6Q35101976-93AC9F9F-6903-4893-9D4E-7B2FAD13ED39Q35123236-5FD689A1-610E-4FCB-890C-13B45BD1D99C
P2860
Low-energy femoral shaft fractures associated with alendronate use.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Low-energy femoral shaft fractures associated with alendronate use.
@en
Low-energy femoral shaft fractures associated with alendronate use.
@nl
type
label
Low-energy femoral shaft fractures associated with alendronate use.
@en
Low-energy femoral shaft fractures associated with alendronate use.
@nl
prefLabel
Low-energy femoral shaft fractures associated with alendronate use.
@en
Low-energy femoral shaft fractures associated with alendronate use.
@nl
P2093
P1476
Low-energy femoral shaft fractures associated with alendronate use.
@en
P2093
Andrew S Neviaser
Brett A Lenart
Dean G Lorich
Folorunsho Edobor-Osula
Joseph M Lane
P304
P356
10.1097/BOT.0B013E318172841C
P577
2008-05-01T00:00:00Z